Northridge, California, USA, November 17, 2026
MiniMed has announced that the U.S. Food and Drug Administration (FDA) has cleared MiniMed Fit™, the company’s first tubeless insulin pump, introducing a new insulin delivery option for people living with Type 1 and Type 2 diabetes. The device combines up to seven days of wear, a 300-unit insulin capacity, smartphone app control and advanced SmartGuard™ automated insulin delivery technology. The regulatory clearance represents an important expansion of MiniMed’s diabetes technology portfolio and marks the company’s entry into the tubeless insulin pump segment. Designed to reduce the frequency of device changes and interruptions associated with diabetes management, MiniMed Fit aims to provide greater flexibility for people who require continuous insulin therapy. The system is designed for individuals with Type 1 and Type 2 diabetes aged seven years and older. According to the company, the device combines extended wear duration with automated insulin adjustments, offering a new approach to managing daily insulin requirements while supporting more convenient diabetes care.
Seven-Day Wear and 300-Unit Insulin Capacity
One of the key features of MiniMed Fit is its extended wear duration of up to seven days, which can reduce the number of pump replacement procedures compared with several existing tubeless insulin delivery options. The device has a 300-unit insulin reservoir, providing approximately 50% more insulin capacity than certain competing tubeless systems that hold 200 units. By combining longer wear duration with greater insulin capacity, the technology is designed to reduce the frequency of cartridge and device changes, helping patients manage their treatment with fewer daily interruptions. The seven-day wear period is dependent on individual insulin requirements, with the company indicating that it is achievable for users requiring less than 42 units of insulin per day. The device also features a discreet, waterproof design that can be worn at multiple body locations, including the back of the arm, lower back, upper buttocks, abdomen and thigh. It is designed to be waterproof up to eight feet (2.4 metres) for one hour and 45 minutes. In addition, the system supports smartphone application control through compatible iOS and Android devices. These features are intended to provide greater flexibility for patients during everyday activities, including exercise, work and travel.
SmartGuard Technology Supports Automated Insulin Delivery
MiniMed Fit incorporates the company’s established SmartGuard™ automated insulin delivery technology, which continuously adjusts insulin delivery based on glucose information from compatible continuous glucose monitoring (CGM) sensors. The system can automatically adjust insulin delivery and provide correction doses every five minutes, helping users maintain glucose levels within their recommended target range. Another important feature is Meal Detection™ technology, which is designed to provide additional insulin when a meal bolus has been missed or underestimated. This capability may help address certain challenges associated with mealtime insulin management. At commercial launch, the system is expected to offer compatibility with two all-in-one sensors: Simplera Sync™, with up to seven days of wear, and Instinct™, manufactured by Abbott, with up to 15 days of wear. MiniMed also reports that real-world users of its SmartGuard technology have achieved up to 80% Time in Range and 91% overnight Time in Range with recommended settings. These figures are based on existing SmartGuard system data and should not be interpreted as guaranteed outcomes for every MiniMed Fit user. The pump is compatible with Humalog, NovoLog and Admelog insulin formulations, according to the company’s announcement.
U.S. Commercial Launch Planned for 2027
The FDA clearance is an important milestone in MiniMed’s broader strategy to expand its automated insulin delivery ecosystem and strengthen its position in the global diabetes technology market. The company expects a phased commercial rollout of MiniMed Fit in the United States during spring 2027, following an early customer experience phase anticipated to begin in its fourth fiscal quarter of 2027. MiniMed is also preparing its manufacturing capacity and commercial infrastructure to support the anticipated launch and future demand. The device is expected to be available through the pharmacy channel, providing patients with an additional access option for obtaining insulin delivery technology. MiniMed CEO Que Dallara highlighted that the new system brings the company’s established insulin automation capabilities into a tubeless design, addressing the demand for greater convenience without compromising diabetes management technology. The company is also planning future integration with its next-generation fully closed-loop technology, which remains investigational and is not currently an approved feature of MiniMed Fit. Overall, the FDA clearance of MiniMed Fit represents a significant development in diabetes medical technology, combining extended device wear, increased insulin capacity and automated delivery features. The innovation could contribute to improving treatment convenience and reducing the daily management burden for eligible people living with diabetes.
Source: MiniMed press release



